Related references
Note: Only part of the references are listed.250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study (vol 8, pg 889, 2009)
P. O'Connor
LANCET NEUROLOGY (2012)
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study (vol 8, pg 889, 2009)
P. O'Connor et al.
LANCET NEUROLOGY (2011)
Anti-JC Virus Antibodies: Implications for PML Risk Stratification
Leonid Gorelik et al.
ANNALS OF NEUROLOGY (2010)
Interferon beta inhibits the Th17 cell-mediated autoimmune response in patients with relapsing-remitting multiple sclerosis
Xin Zhang et al.
CLINICAL NEUROLOGY AND NEUROSURGERY (2010)
Fingolimod for relapsing multiple sclerosis: an update
Alejandro Horga et al.
EXPERT OPINION ON PHARMACOTHERAPY (2010)
Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
James J. Marriott et al.
NEUROLOGY (2010)
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Ludwig Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Jeffrey A. Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial
G. Comi et al.
LANCET (2009)
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial
Ludwig Kappos et al.
LANCET NEUROLOGY (2009)
Progressive Multifocal Leukoencephalopathy after Natalizumab Monotherapy
Hans Linda et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study (vol 8, pg 889, 2009)
P. O'Connor et al.
LANCET NEUROLOGY (2009)
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study
Paul O'Connor et al.
LANCET NEUROLOGY (2009)
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial
Daniel D. Mikol et al.
LANCET NEUROLOGY (2008)
Four new cases of therapy-related acute promyelocytic leukemia after mitoxantrone
I. Bosca et al.
NEUROLOGY (2008)
The incidence and significance of anti-natalizumab antibodies -: Results from AFFIRM and SENTINEL
P. A. Calabresi et al.
NEUROLOGY (2007)
Natalizumab for multiple sclerosis
Richard M. Ransohoff
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis
F. Paul et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2007)
Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial
Jerry S. Wolinsky et al.
ANNALS OF NEUROLOGY (2007)
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes
L. Kappos et al.
NEUROLOGY (2006)
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
CH Polman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis
RA Rudick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy
TA Yousry et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Effect of mitoxantrone on MRI in progressive MS - Results of the MIMS trial
H Krapf et al.
NEUROLOGY (2005)
Brief report - Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis
BK Kleinschmidt-DeMasters et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Brief report - Progressive multifocal leukoencephalopathy in a patient treated with natalizumab
A Langer-Gould et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Brief report - Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease
G Van Assche et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis
PS Sorensen et al.
LANCET (2003)
Rapid onset Mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis
JR Avasarala et al.
MULTIPLE SCLEROSIS (2003)
Mitoxantrone in progressive multiple sclerosis:: a placebo-controlled, double-blind, randomised, multicentre trial
HP Hartung et al.
LANCET (2002)
Randomized, comparative study of interferon β-1a treatment regimens in MS -: The EVIDENCE trial
H Panitch et al.
NEUROLOGY (2002)
Copaxone's effect on MRI-monitored disease in relapsing MS is reproducible and sustained
JS Wolinsky et al.
NEUROLOGY (2002)
Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN)
L Durelli et al.
LANCET (2002)
Effect of early interferon treatment on conversion to definite multiple sclerosis:: a randomised study
G Comi et al.
LANCET (2001)
European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis
G Comi et al.
ANNALS OF NEUROLOGY (2001)
Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis.
LD Jacobs et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS - Quantitative MR assessment
Y Ge et al.
NEUROLOGY (2000)
Share Paper
